MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs.

We have developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. We are currently developing a portfolio of anti-infective PULSYS products. Our near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades.

MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG - the first and only FDA-approved once-daily amoxicillin. While the company is currently focused on the anti-infective arena, MiddleBrook sees opportunities for PULSYS® products in the anti-fungal, antiviral, and oncology markets as well. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

We have 300 field force representatives and district managers that call on primary care physicians across the nation. Our field force currently details physicians on the benefits of our once-daily amoxicillin product, MOXATAG®, and it has the capacity to add another product to its detail efforts. The ideal product would align well with our targeted health care professional population, which are primary care physicans. We are also open to other business development opportunities.